WeVote
Log In

Bill

Bill

SB 1797

essential drugs; price increases; limits.

57th Legislature - Second Regular Session Introduced by Flavio Bravo and 5 co-sponsors

Arizona bill caps annual price increases for essential drugs to control medication costs and improve patient affordability.

Senate Second Reading
0
WeVote Research Nonpartisan
Bill Summary · SB 1797

Legislative bill overview

SB 1797 would establish limits on price increases for essential drugs in Arizona, likely requiring manufacturers or distributors to justify or cap annual price hikes above a certain threshold. The bill aims to make necessary medications more affordable by controlling what sponsors consider excessive pricing practices.

Why is this important

Drug pricing directly affects patients' ability to afford life-sustaining medications. Uncontrolled price increases can force individuals to choose between medications and other necessities, potentially leading to worse health outcomes and increased healthcare system costs through emergency care and hospitalizations.

Potential points of contention

  • Pharmaceutical industry opposition: Drug manufacturers argue price controls limit innovation funding and R&D investment for new treatments, potentially reducing future drug development
  • Definitional challenges: "Essential drugs" and "excessive" price increases require precise definition to avoid unintended consequences like market withdrawal of certain medications
  • Interstate commerce concerns: Federal law and interstate commerce rules may limit Arizona's ability to regulate drug pricing without broader state or federal coordination
  • Implementation complexity: Determining which drugs qualify, setting appropriate thresholds, and enforcement mechanisms require significant regulatory infrastructure

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.